Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
2.320
+0.080 (3.57%)
At close: Feb 27, 2026, 4:00 PM EST
2.280
-0.040 (-1.72%)
Pre-market: Mar 2, 2026, 7:00 AM EST
Century Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Century Therapeutics stock have an average target of 3.50, with a low estimate of 2.00 and a high estimate of 6.00. The average target predicts an increase of 50.86% from the current stock price of 2.32.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 20, 2026.
Analyst Ratings
The average analyst rating for Century Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $2 → $4 | Buy | Maintains | $2 → $4 | +72.41% | Jan 20, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $7 → $2 | Buy → Hold | Downgrades | $7 → $2 | -13.79% | Nov 17, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +158.62% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | -13.79% | Apr 3, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 28, 2025 |
Financial Forecast
Revenue This Year
111.36M
from 6.59M
Increased by 1,590.09%
Revenue Next Year
n/a
from 111.36M
EPS This Year
-0.14
from -1.61
EPS Next Year
-0.53
from -0.14
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 114.7M | n/a | ||||
| Avg | 111.4M | n/a | ||||
| Low | 107.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,640.2% | - | ||||
| Avg | 1,590.1% | - | ||||
| Low | 1,523.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.14 | -0.37 | |
| Avg | -0.14 | -0.53 | |
| Low | -0.14 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.